CONTRAINDICATIONS:
NAPRELAN® is contraindicated in patients with known hypersensitivity
to naproxen. NAPRELAN® should not be given to patients who have experienced
asthma, urticaria, or allergic-type reations after taking aspirin or other NSAIDs.
Severe, rarely fatal, anaphylactic-like reations to NSAIDs have been reported in
such patients.
Cardiovascular Risk
- NSAIDs may cause an increased risk of serious cardiovascular thrombotic events,
myocardial infarction, and stroke, which can be fatal. This risk may increase with
duration of use. Patients with cardiovascular disease or risk factors for cardiovascular
disease may be at greater risk (see WARNINGS).
- Naproxen as NAPRELAN® is contraindicated for the treatment of peri-operative
pain in the setting of coronary artery bypass graft (CABG) surgery (see WARNINGS).
Gastrointestinal Risk
- NSAIDs cause an increased risk of serious gastrointestinal adverse events including
bleeding, ulceration, and perforation of the stomach on intestines, which can be
fatal. These events can occur at any time during use and without warning symptoms.
Elderly patients are at greater risk for serious gastrointestinal events (see WARNINGS).
NAPRELAN® is a registered trademark of Elan Corporation plc. IPDAS®
is a registed trademark of Elan Corporation International Ltd.